An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

NCT04820309 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

566

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Xanomeline and Trospium Chloride Capsules

Sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company